Por favor, use este identificador para citar o enlazar a este item:
http://hdl.handle.net/10261/184795
COMPARTIR / EXPORTAR:
SHARE CORE BASE | |
Visualizar otros formatos: MARC | Dublin Core | RDF | ORE | MODS | METS | DIDL | DATACITE | |
Campo DC | Valor | Lengua/Idioma |
---|---|---|
dc.contributor.author | Rodríguez-Carrio, Javier | es_ES |
dc.contributor.author | Alperi-López, Mercedes | es_ES |
dc.contributor.author | López-Mejías, Raquel | es_ES |
dc.contributor.author | López, Patricia | es_ES |
dc.contributor.author | Ballina García, Francisco Javier | es_ES |
dc.contributor.author | Abal, Francisco | es_ES |
dc.contributor.author | González-Gay, M. A. | es_ES |
dc.contributor.author | Suárez, Ana | es_ES |
dc.date.accessioned | 2019-06-25T09:46:14Z | - |
dc.date.available | 2019-06-25T09:46:14Z | - |
dc.date.issued | 2016-09-22 | - |
dc.identifier.citation | Clinical Science 130 (21): 1889-1899 (2016) | es_ES |
dc.identifier.issn | 0143-5221 | - |
dc.identifier.uri | http://hdl.handle.net/10261/184795 | - |
dc.description.abstract | Traditional and non-traditional cardiovascular (CV) risk factors underlie CV disease occurrence in rheumatoid arthritis (RA). Recently, a functional impairment of high-density lipoprotein (HDL) has been observed. Although the actual players are unknown, anti-HDLs were associated with altered lipid profile, decreased paraoxonase 1 (PON1) activity and CV disease in RA. Therefore, we aimed to evaluate whether the presence of antibodies against PON1 may be involved in this scenario. IgG anti-PON1 antibodies were quantified by ELISA in serum samples from 212 RA patients, 175 healthy controls (HC) and 54 subjects with traditional CV risk factors (CVR). A subgroup of 13 RA patients was prospectively followed upon tumour necrosis factor-α (TNFα) blockade. Serum PON1 activity, nitric oxide (NO) and total antioxidant capacity (TAC) were measured. Interferon-γ (IFNγ), interleukin 8 (IL-8), monocyte chemotactic protein 1 (MCP-1), vascular endothelial growth factor (VEGF), soluble intercellular adhesion molecule (sICAM) and TNFα serum levels were assessed by immunoassays. PON1 rs662 (Q > R) status was studied by reverse transcription (RT)–PCR. IgG anti-PON1 antibodies are increased in RA patients compared with HC (P<0.0001) and CVR subjects (P<0.001), even after correcting for total IgG levels. Although no associations with lipid profile were found, a positive correlation with Health Assessment Questionnaire (HAQ) was observed (r=0.215, P=0.004). Anti-PON1 antibodies were associated with PON1 activity, NO and TAC, a rs662-mediated gene-dosage effect being found. Similarly, anti-PON1 antibodies were associated with sICAM serum levels in univariate and multivariate models. Finally, these antibodies were not affected by TNFα blockade. Anti-PON1 antibodies can be responsible for PON1 impairment in RA patients, with a potential impact on biomarkers of oxidative status and endothelial activation. A gene–environment interaction of rs662 variants is supported. | es_ES |
dc.description.sponsorship | This work was supported by the European Union FEDER funds and ‘Fondo de Investigación Sanitaria’ (ISCIII, Health Ministry, Spain) [grant numbers PI12/00523, PI12/00060 and PI15/00525]; the RETICS Programs (ISCIII, Health Ministry, Spain) [grant number RD12/0009 (RIER)]; the Spanish Society for Rheumatology (SER) [travel grant (to J.R.-C.)]; the FICYT (Fundación para el fomento en Asturias de la Investigación Científica aplicada y la Tecnología) [grant number GRUPIN14-043 (to J.R.-C.)]; and the RETICS Program (RIER) [grant number RD12/0009/0013 (to R.L.M.)] | es_ES |
dc.language.iso | eng | es_ES |
dc.publisher | Portland Press | es_ES |
dc.rights | closedAccess | es_ES |
dc.subject | Anti-paraoxonase 1 antibodies | es_ES |
dc.subject | Cardiovascular disease | es_ES |
dc.subject | High-density lipoproteins | es_ES |
dc.subject | Paraoxonase | es_ES |
dc.subject | Rheumatoid arthritis | es_ES |
dc.title | Antibodies to paraoxonase 1 are associated with oxidant status and endothelial activation in rheumatoid arthritis | es_ES |
dc.type | artículo | es_ES |
dc.identifier.doi | 10.1042/CS20160374 | - |
dc.description.peerreviewed | Peer reviewed | es_ES |
dc.relation.publisherversion | http://dx.doi.org/10.1042/CS20160374 | es_ES |
dc.identifier.e-issn | 1470-8736 | - |
dc.contributor.funder | European Commission | es_ES |
dc.contributor.funder | Instituto de Salud Carlos III | es_ES |
dc.contributor.funder | Sociedad Española de Reumatología | es_ES |
dc.contributor.funder | Fundación para el Fomento en Asturias de la Investigación Científica Aplicada y la Tecnología | es_ES |
dc.relation.csic | Sí | es_ES |
oprm.item.hasRevision | no ko 0 false | * |
dc.identifier.funder | http://dx.doi.org/10.13039/501100004587 | es_ES |
dc.identifier.funder | http://dx.doi.org/10.13039/501100008430 | es_ES |
dc.identifier.funder | http://dx.doi.org/10.13039/501100000780 | es_ES |
dc.contributor.orcid | Rodríguez-Carrio, Javier [0000-0002-0011-5102] | es_ES |
dc.contributor.orcid | López, Patricia [0000-0002-1843-0653] | es_ES |
dc.contributor.orcid | Suárez, Ana [0000-0002-4452-7539] | es_ES |
dc.type.coar | http://purl.org/coar/resource_type/c_6501 | es_ES |
item.cerifentitytype | Publications | - |
item.openairecristype | http://purl.org/coar/resource_type/c_18cf | - |
item.grantfulltext | none | - |
item.openairetype | artículo | - |
item.fulltext | No Fulltext | - |
item.languageiso639-1 | en | - |
Aparece en las colecciones: | (IPLA) Artículos |
Ficheros en este ítem:
Fichero | Descripción | Tamaño | Formato | |
---|---|---|---|---|
accesoRestringido.pdf | 15,35 kB | Adobe PDF | Visualizar/Abrir |
CORE Recommender
SCOPUSTM
Citations
14
checked on 24-abr-2024
WEB OF SCIENCETM
Citations
14
checked on 25-feb-2024
Page view(s)
280
checked on 26-abr-2024
Download(s)
34
checked on 26-abr-2024
Google ScholarTM
Check
Altmetric
Altmetric
NOTA: Los ítems de Digital.CSIC están protegidos por copyright, con todos los derechos reservados, a menos que se indique lo contrario.